A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Recruiting

Phase 2

TebentafuspA Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Sponsor:

Sarcoma Alliance for Research through Collaboration

Code:

NCT06942442

Conditions

HLA-A*0201 Positive Cells Present

Clear Cell Sarcoma (CCS)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Physician's Choice

Tebentafusp

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-02. This information was provided to ClinicalTrials.gov by Sarcoma Alliance for Research through Collaboration on 2025-10-28.